NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

IMMUNOVIA PUBLISHES PROSPECTUS IN CONNECTION WITH RIGHTS ISSUE

The board of directors of Immunovia AB (publ) ("Immunovia" or the "Company") has prepared a prospectus (the "Prospectus") relating to the rights issue of units of approximately SEK 63.4 million, which was resolved by the board of directors on 28 September 2026, and approved by the extraordinary general meeting held on 29 October 2026 (the "Rights Issue"). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

Summary

· Anyone who is registered as a shareholder in Immunovia on the record date, 5 November 2026, will receive eleven (11) unit rights for each (1) existing share in the Company. Seven (7) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of two (2) shares and one (1) warrant of series TO 4. The warrants of series TO 4 are intended to be admitted to trading on Nasdaq Stockholm.
· The Rights Issue entails the issuance of a maximum of 1,057,047,973 units, corresponding to 2,114,095,946 shares and 1,057,047,973 warrants of series TO 4.
· The subscription price in the Rights Issue has been set to SEK 0.06 per unit, corresponding to SEK 0.03 per share. The warrants of series TO 4 are issued free of charge.
· One (1) warrant of series TO 4 entitles the holder to subscription of one (1) new share in the Company during the period from and including 19 April 2027 up to and including 3 May 2027, at an exercise price of SEK 0.03, corresponding to 110 percent of the subscription price per share in the Rights Issue rounded to the nearest whole öre.
· Upon full subscription in the Rights Issue, Immunovia will initially receive approximately SEK 63.4 million before issue costs. In the event the warrants of series TO 4 are fully exercised for subscription of new shares, the Company will receive additional proceeds of approximately SEK 31.7 million in May 2027, before issue costs.
· The subscription period in the Rights Issue will run from and including 9 November 2026 up to and including 23 November 2026.
· Immunovia intends to use the net proceeds from the Rights Issue to fund the continued US commercialization of PancreaSure, including targeted investment in sales and marketing, to fund ongoing clinical studies to demonstrate the clinical usefulness of the PancreaSure test to support reimbursement, and to provide working capital for general corporate purposes.
· The Rights Issue is covered to approximately SEK 1 million by subscription undertakings and to SEK 49 million by a bottom guarantee commitment, corresponding to a total of

approximately 78.8 percent of the Rights Issue.

For complete information on the Rights Issue, please see the published Prospectus.

The Prospectus
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on 4 November 2026, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company's website (**www.immunovia.com**) and Vator Securities AB's website (**www.vatorsecurities.se**). The Prospectus will also be available on the Swedish Financial Supervisory Authority's website (**www.fi.se**). Subscription forms will be available on the Company's and Vator Securities AB's respective websites.

Time plan for the Rights Issue

First day of trading in shares excluding right to receive unit rights	4 November 2026
Record date for the right to receive unit rights	5 November 2026
Trading in unit rights	9 – 18 November 2026
Subscription period	9 – 23 November 2026
Announcement of the outcome of the Rights Issue	Around 25 November 2026
Trading in paid subscribed units (BTU)	9 November – 10 December 2026

Advisers
APREA Partners AB acts as global coordinator and joint bookrunner and Carlsquare AB acts as joint bookrunner in connection with the Rights Issue. Ascente Law AB is legal adviser to Immunovia in connection with the Rights Issue. Vator Securities AB acts as issuing agent in connection with the Rights Issue.

For further information, please contact:
Jeff Borcherding, CEO
E-mail: jeff.borcherding@immunovia.com

This information was submitted for publication, through the agency of the contact person set out above, on 4 November 2026 at 14.00 CET.

IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Immunovia. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for units in Immunovia has only been made through the Prospectus that the Company has published on 4 November 2026. The Prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, **www.immunovia.com**. The approval of the Prospectus by the Swedish Financial Supervisory

Authority shall not be regarded as an approval of the shares, warrants or any other securities. This release is not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 ("**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Immunovia. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety. In accordance with article 2 k of the Prospectus Regulation, this press release constitutes an **advertisement**.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares, warrants or other securities in Immunovia have been registered, and no shares, warrants or other securities will be registered, under the United States Securities Act of 1933, as amended (the "**Securities Act**") or the securities legislation of any state or other jurisdiction in the United States of America and no shares, warrants or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

Within the European Economic Area ("**EEA**"), no public offering of shares, warrants or other securities ("**Securities**") is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of

this press release and should not act or rely on it.
This press release may contain forward-looking statements which reflect the Company's current view on future events and financial and operational development. Words such as "*intend*", "*will*", "*expect*", "*anticipate*", "*may*", "*believe*", "*plan*", "*estimate*" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements.
Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.
This information, opinions and forward-looking statements contained in this press release applies only as of the date hereof and may be subject to change without notice. Immunovia makes no commitment to publicly update or revise any forward-looking statements, future events or similar circumstances other than as required by applicable law.
APREA Partners AB and Carlsquare AB are acting for Immunovia in connection with the transaction and no one else, and will not be responsible to anyone other than Immunovia for providing the protections afforded to their respective clients nor for giving advice in relation to the transaction or any other matter referred to herein.
Since Immunovia conducts essential services according to the Swedish Screening of Foreign Direct Investments Act (*Sw*. lag (2023:560) om granskning av utländska direktinvesteringar), certain investments in the Rights Issue may require review by the Inspectorate of Strategic Products (ISP). More information about this can be found on the Company's website **www.immunovia.com**.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit **www.immunovia.com**.